YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Adaptive Biotechnologies now sits on a higher modeled fair value, with the price target moving from US$26.36 to US$28.31 per share. This shift reflects how analysts are weighing strong enthusiasm around the clonoSEQ minimal residual diseas…
Adaptive Biotechnologies has seen its share price move sharply in recent years, and the question now is whether the cash flows the business can generate really back up that kind of ride. With the stock recently closing at US$29.57 and inve…
Adaptive Biotechnologies Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells SEATTLE, Sept. 25, 2026 (GLOBE NEWS…
Adaptive Biotechnologies (ADPT) is back in focus after the National Comprehensive Cancer Network updated multiple myeloma guidelines to more fully embed minimal residual disease testing and explicitly reference the company's clonoSEQ assay…
Adaptive Biotechnologies recently highlighted updates to the National Comprehensive Cancer Network multiple myeloma guidelines, which now feature a dedicated page on minimal residual disease testing and specifically reference its FDA-clear…
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) highlighted updated National Comprehensive Cancer Network, or NCCN, multiple myeloma guidelines on September 17. According to the announcement, the recommendations specifically name clonoS…
Mid-cap U.S. healthcare stocks have exhibited strong momentum traits year to date, with several names earning A-range momentum grades that indicate stronger price performance trends relative to sector peers. Seeking Alpha's Quant Momentum…
Adaptive Biotechnologies Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferr…
Adaptive Biotechnologies SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clini…
(RTTNews) - As Warren Buffett once said, "If you find three wonderful businesses in your life, you'll get very rich." His message underscores the importance of identifying a handful of exceptional companies capable of delivering sustained…
Shares of Adaptive Biotechnologies (ADPT) have been strong performers lately, with the stock up 14.1% over the past month. The stock hit a new 52-week high of $24.34 in the previous session. Adaptive Biotechnologies has gained 48.9% since…
(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), a commercial-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss amid revenue growth. In addition, the company a…
This article first appeared on GuruFocus. Total Revenue: $71.6 million, up 30% year-over-year. MRD Revenue: $66.2 million, up 33% year-over-year; core MRD revenue (excluding milestones) grew 49%. Clinical Revenue (MRD): Increased 53% year-…
Adaptive Biotechnologies (ADPT) reported $71.55 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 21.5%. EPS of -$0.10 for the same period compares to -$0.17 a year ago. The reported revenue repr…
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring it…
Adaptive Biotechnologies SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adapt…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Investors are watching Adaptive Biotechnologies (ADPT) after forecasts pointed to a reduced quarterly loss of $0.13 per…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Adaptive Biotechnologies stock has delivered very strong total returns over the past three years, while its valuation signals are p…
Wall Street expects a year-over-year increase in earnings on higher revenues when Agios Pharmaceuticals (AGIO) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's…
Earlier this week, Adaptive Biotechnologies was upgraded to a Zacks Rank #2 (Buy) following upward revisions to its earnings estimates and expectations for a smaller quarterly loss alongside higher revenue for the June 2026 quarter. This s…
The market expects Adaptive Biotechnologies (ADPT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing t…
Adaptive Biotechnologies (ADPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is DexCom (DXCM) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find ou…
Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52…
Key Points Approximately 386,000 shares were liquidated for a total transaction value of $8.5 million on July 2, 2026. This transaction consisted entirely of directly held shares. The sale was executed under a Rule 10b5-1 trading plan adop…
Harlan S. Robins, the chief scientific officer of Adaptive Biotechnologies Corporation (NASDAQ:ADPT), sold 386,240 shares of common stock at $22.01 per share on July 2, 2026, according to an SEC Form 4 filing. Transaction summary Metric Va…
Adaptive Biotechnologies SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinic…
Cathie Wood, head of Ark Investment Management, is known for buying her favorite tech stocks during market pullbacks. That's exactly what she just did, adding shares of an AI stock after a sharp selloff. In 2025, the flagship Ark Innovatio…
Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies for trial enrollment and precisely evaluate treatment response BOSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech,…
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Hematologic Malignancies Testing Market size & share revenue was valued at approximate…
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the Best Growth Stocks to Buy and Hold for the Next Decade. On June 17, BTIG maintained a Buy rating on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) with a $22 price targe…
Adaptive Biotechnologies Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of…
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Tuesday. Stock index futures (SPX [https://seekingalpha.com/symbol/SPX]) were muted on Tues…
Adaptive Biotechnologies Corporation (ADPT [https://seekingalpha.com/symbol/ADPT]) shares tumbled over 9% in premarket trading on Tuesday, following a dual announcement on Monday afternoon detailing a planned structural separation [https:/…
[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures were muted on Tuesday while oil prices continued to drift downward. Wall Street went into a waiting mode as investors looked for more con…
(RTTNews) - Adaptive Biotechnologies Corporation (ADPT), a commercial-stage biotechnology company, announced its intention to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. In addition, it unveils plans to offe…